Next Article in Journal
Survival Bias and Crosstalk between Chronological and Behavioral Age: Age- and Genotype-Sensitivity Tests Define Behavioral Signatures in Middle-Aged, Old, and Long-Lived Mice with Normal and AD-Associated Aging
Next Article in Special Issue
Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma
Previous Article in Journal
A Tissue-Engineered Tracheobronchial In Vitro Co-Culture Model for Determining Epithelial Toxicological and Inflammatory Responses
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 9
Issue 6
10.3390/biomedicines9060633
Review Report
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo

Biomedicines 2021, 9(6), 633; https://doi.org/10.3390/biomedicines9060633
by Chandra K. Maharjan 1, Shaikamjad Umesalma 1, Courtney A. Kaemmer 1, Viviane P. Muniz 1, Casey Bauchle 2, Sarah L. Mott 3, K. D. Zamba 3,4, Patrick Breheny 3,4, Mariah R. Leidinger 5, Benjamin W. Darbro 3,6, Samuel B. Stephens 2, David K. Meyerholz 5 and Dawn E. Quelle 1,3,5,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Biomedicines 2021, 9(6), 633; https://doi.org/10.3390/biomedicines9060633
Submission received: 27 April 2021 / Revised: 26 May 2021 / Accepted: 28 May 2021 / Published: 2 June 2021
(This article belongs to the Special Issue Feature Papers in Cancer Biology and Therapeutics)

Round 1

Reviewer 1 Report

In this manuscript, the authors have investigated the role of RABL6A in neuroendocrine tumor. The concluded that RABL6A promotes pancreatic neuroendocrine tumor angiogenesis and progression in vivo. This is an interesting study. The authors should consider the below points to improve the manuscript.

  1. The authors should include in vitro data to further confirm the oncogenic role of RABL6A.
  2. The expression of angiogenesis markers such as VEGF should be included in Figure 4.
  3. In addition to Myc, include a couple of other biomarkers of pNET to support the conclusions. 
  4. Immunohistochemistry data is needed for RBAL6A to support their findings. 
  5. ARF and Myc immunohistochemistry data should be provided.

Author Response

Please see the attachment. 

Author Response File: Author Response.pdf

Reviewer 2 Report

The manuscript has investigated the role of RABL6A in pNETs. The conclusion is well supported by the data. The regulatory effect of RABL6A has been investigated in a mouse model and the results are supported by the data. I have following concerns

  1. Please cite line 41-43
  2. Please mention the groups and the number of mice in each group and experiment used for the studies in the animal model in methods section
  3. Figure 1: This Mouse models to study the in vivo role of RABL6A in pNET pathogenesis- is not a clear title, please modify
  4. Why the expression of GAPDH in western analysis of p19ARF and GAPDH # 1 and 4 is so low while this is not the case in upper panel?
  5. The results suggest that RABL6A regulate expression of c-myc, angiogenic switch, and mitosis; please support these findings by knocking down RABL6A in pNETs cell line using siRNA or knocking out RABL6A to have a direct evidence because change in expression of c-myc, angiogenic switch (VEGF, EGF, PI3K/Akt/mTOR, PKCs, Ras/MAPK) and mitosis might be due to multiple factors.

Author Response

Please see the attachment. 

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

The authors have addressed all the comments appropriately and the manuscript can be accepted for publication.

Back to TopTop